Princeton Junction, NJ, United States of America

Vedrana Stojanovic-Susulic

USPTO Granted Patents = 18 (Patent Applications = 2)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 7.8

ph-index = 9

Forward Citations = 362(Granted Patents)

Location History:

Princeton, NJ (US) (2010 - 2012)
Malvern, PA (US) (2012)
Radnor, PA (US) (2011 - 2013)
Spring House, PA (US) (2016)
Princeton Junction, NJ (US) (2007 - 2024)

Company Filing History:

9 out of 27

Applied Molecular Evolution

patents

9 out of 410

Janssen Biotech, Inc.

Codman & Shurtleff, Inc.

patents

5. 1 out of 31

Centocor Ortho Biotech Inc.

7. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12065488 - Anti-IL-6 antibody (2024-08-20),

2. 11180549 - Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody (2021-11-23),

3. 9631016 - Pen-injector device containing anti-IL-6 antibodies (2017-04-25),

4. 9481731 - Toll-like receptor 3 antagonists (2016-11-01),

5. 9340613 - Anti-IL-6 antibodies, compositions, methods and uses (2016-05-17),

6. 8623362 - Anti-IL-6 antibodies (2014-01-07),

7. 8460659 - Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases (2013-06-11),

8. RE43672 - Anti-IL-6 antibodies, compositions, methods and uses (2012-09-17),

9. 8252744 - Implantable pump for protein delivery for obesity control by drug infusion into the brain (2012-08-28),

10. 8226611 - Anti-IL-6 antibodies, compositions, methods and uses (2012-07-24),

11. 8153583 - Toll like receptor 3 antagonists, methods and uses (2012-04-10),

12. 8067003 - Methods of treating conditions using anti-IL-6 antibodies (2011-11-29),

13. 7910101 - Melanocortin receptor binding mimetibodies, compositions, methods and uses (2011-03-22),

14. 7833755 - Anti-IL-6 antibody nucleic acid molecules and methods (2010-11-16),

15. 7833531 - Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists (2010-11-16),

Title: The Innovative Contributions of Vedrana Stojanovic-Susulic

Introduction: Vedrana Stojanovic-Susulic is a prominent inventor based in Princeton Junction, NJ, who has made significant strides in the field of biotechnology. With a remarkable portfolio of 18 patents, her innovations, especially in the treatment of IL-6 related conditions, have the potential to revolutionize therapies for diseases like rheumatoid arthritis.

Latest Patents: Among her latest patents are notable inventions pertaining to anti-IL-6 antibodies. These include a patent specifically focused on anti-IL-6 antibodies and antirheumatics, which are pivotal in treating and suppressing IL-6 related conditions such as rheumatoid arthritis. Another patent details methods of suppressing rheumatoid arthritis using these innovative anti-IL-6 antibodies, reinforcing her commitment to advancing medical science in this area.

Career Highlights: Vedrana has held pivotal roles at renowned companies in the biotechnology sector, including Applied Molecular Evolution and Janssen Biotech, Inc. Her work in these organizations has been instrumental in pushing the boundaries of understanding and treating complex diseases.

Collaborations: Throughout her career, Vedrana has collaborated with esteemed professionals including Raymond W. Sweet and Sheng-Jiun Wu. These collaborations have contributed to her research and development efforts, fostering a spirit of innovation and teamwork.

Conclusion: Vedrana Stojanovic-Susulic exemplifies the spirit of innovation through her extensive work in biotechnology. Her numerous patents reflect a dedication to enhancing medical treatments, particularly in managing IL-6 related conditions. As she continues her groundbreaking work, her contributions are poised to make a lasting impact on the medical community and improve the lives of many.

This text is generated by artificial intelligence and may not be accurate.